Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1993 Jun;52(6):423–428. doi: 10.1136/ard.52.6.423

Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient?

H A Capell 1, D R Porter 1, R Madhok 1, J A Hunter 1
PMCID: PMC1005066  PMID: 8100702

Abstract

OBJECTIVES--The objectives were to assess (a) the comparative merits of commonly used disease modifying drugs in the treatment of rheumatoid arthritis (RA) and (b) the influence of age, gender, and disease duration on the outcome of treatment. METHODS--Collected analysis (meta-analysis) was performed on results obtained during the first year of treatment in 1140 patients with RA treated with gold, penicillamine, sulphasalazine, or auranofin from a single centre. RESULTS--Gold, penicillamine, and sulphasalazine performed similarly, with about 60% of patients continuing to receive each of these drugs for at least one year. Neither gender nor age had an influence on the response to treatment, but patients with a longer disease duration showed a greater tendency to stop treatment. The median percentage improvement was 33% in visual analogue pain score and 50% in erythrocyte sedimentation rate. CONCLUSIONS--Routine use of these drugs should at least equal these results. Any new drug should either be substantially less toxic or at least as efficacious.

Full text

PDF
423

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bendix G., Bjelle A. Outcome of parenteral gold therapy in RA patients: a comparison between two periods using life-table analysis. Br J Rheumatol. 1991 Dec;30(6):407–412. doi: 10.1093/rheumatology/30.6.407. [DOI] [PubMed] [Google Scholar]
  2. Capell H. A., Brzeski M. Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis. Ann Rheum Dis. 1992 Mar;51(3):424–429. doi: 10.1136/ard.51.3.424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Capell H. A., Lewis D., Carey J. A three year follow up of patients allocated to placebo, or oral or injectable gold therapy for rheumatoid arthritis. Ann Rheum Dis. 1986 Sep;45(9):705–711. doi: 10.1136/ard.45.9.705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Capell H. A., Murphy E. A., Hunter J. A. Rheumatoid arthritis: workload and outcome over 10 years. Q J Med. 1991 Jun;79(290):461–476. [PubMed] [Google Scholar]
  5. Felson D. T., Anderson J. J., Meenan R. F. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum. 1990 Oct;33(10):1449–1461. doi: 10.1002/art.1780331001. [DOI] [PubMed] [Google Scholar]
  6. Grindulis K. A., McConkey B. Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone. Ann Rheum Dis. 1984 Jun;43(3):398–401. doi: 10.1136/ard.43.3.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Madhok R., Zoma A., Torley H. I., Capell H. A., Waring R., Hunter J. A. The relationship of sulfoxidation status to efficacy and toxicity of penicillamine in the treatment of rheumatoid arthritis. Arthritis Rheum. 1990 Apr;33(4):574–577. doi: 10.1002/art.1780330416. [DOI] [PubMed] [Google Scholar]
  8. Paulus H. E., Egger M. J., Ward J. R., Williams H. J. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum. 1990 Apr;33(4):477–484. doi: 10.1002/art.1780330403. [DOI] [PubMed] [Google Scholar]
  9. Porter D., Madhok R., Hunter J. A., Capell H. A. Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis. Ann Rheum Dis. 1992 Apr;51(4):461–464. doi: 10.1136/ard.51.4.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Pullar T., Capell H. A. A rheumatological dilemma: is it possible to modify the course of rheumatoid arthritis? Can we answer the question? Ann Rheum Dis. 1985 Feb;44(2):134–140. doi: 10.1136/ard.44.2.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pullar T., Hunter J. A., Capell H. A. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann Rheum Dis. 1985 Dec;44(12):831–837. doi: 10.1136/ard.44.12.831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pullar T., Hunter J. A., Capell H. A. Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann Rheum Dis. 1987 May;46(5):398–402. doi: 10.1136/ard.46.5.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pullar T., Hunter J. A., Capell H. A. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J (Clin Res Ed) 1983 Oct 15;287(6399):1102–1104. doi: 10.1136/bmj.287.6399.1102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Pullar T., Hunter J. A., Capell H. A. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy. Br J Rheumatol. 1985 Aug;24(3):269–276. doi: 10.1093/rheumatology/24.3.269. [DOI] [PubMed] [Google Scholar]
  15. Sambrook P. N., Browne C. D., Champion G. D., Day R. O., Vallance J. B., Warwick N. Terminations of treatment with gold sodium thiomalate in rheumatoid arthritis. J Rheumatol. 1982 Nov-Dec;9(6):932–934. [PubMed] [Google Scholar]
  16. Scott D. L., Dawes P. T., Fowler P. D., Grindulis K. A., Shadforth M., Bacon P. A. Anti-rheumatic drugs and joint damage in rheumatoid arthritis. Q J Med. 1985 Jan;54(213):49–59. [PubMed] [Google Scholar]
  17. Situnayake R. D., Grindulis K. A., McConkey B. Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods. Ann Rheum Dis. 1987 Mar;46(3):177–183. doi: 10.1136/ard.46.3.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Thompson P. W., Kirwan J. R., Barnes C. G. Practical results of treatment with disease-modifying antirheumatoid drugs. Br J Rheumatol. 1985 May;24(2):167–175. doi: 10.1093/rheumatology/24.2.167. [DOI] [PubMed] [Google Scholar]
  19. Wolfe F., Hawley D. J., Cathey M. A. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol. 1990 Aug;17(8):994–1002. [PubMed] [Google Scholar]
  20. Wolfe F., Hawley D. J. Remission in rheumatoid arthritis. J Rheumatol. 1985 Apr;12(2):245–252. [PubMed] [Google Scholar]
  21. van der Heijde D. M., van Riel P. L., Nuver-Zwart I. H., Gribnau F. W., vad de Putte L. B. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989 May 13;1(8646):1036–1038. doi: 10.1016/s0140-6736(89)92442-2. [DOI] [PubMed] [Google Scholar]
  22. van der Heijde D. M., van Riel P. L., van Rijswijk M. H., van de Putte L. B. Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature. Semin Arthritis Rheum. 1988 May;17(4):284–292. doi: 10.1016/0049-0172(88)90013-3. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES